Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Randomized, Phase 2 Study of R-CHOP Plus Enzastaurin Versus R-CHOP in the First-Line Treatment of Patients With Intermediate and High-Risk Diffuse Large B-Cell Lymphoma.

Trial Profile

An Open-Label, Randomized, Phase 2 Study of R-CHOP Plus Enzastaurin Versus R-CHOP in the First-Line Treatment of Patients With Intermediate and High-Risk Diffuse Large B-Cell Lymphoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Nov 2018

At a glance

  • Drugs Enzastaurin (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 26 Nov 2018 According to Denovo Biopharma media release, data from this study will be presented at the American Society of Hematology Annual Meeting.
    • 17 Jan 2013 Planned end date changed from 1 Sep 2014 to 1 Feb 2013 as reported by ClinicalTrials.gov.
    • 07 Jun 2011 Preliminary (1 year) results presented at the 47th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top